Protara Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2025, on May 8, 2025. The company reported a net loss of $11.9 million, or 29 cents per share. This loss was narrower than the average analyst estimate of 47 cents per share.
The company highlighted significant progress in 2025, including the recent presentation of positive interim results from its ADVANCED-2 trial of TARA-002 in BCG-Unresponsive and BCG-Naïve patients. These results demonstrated durable 12-month landmark responses, reinforcing the potential of TARA-002 in Non-Muscle Invasive Bladder Cancer (NMIBC).
Protara also noted continued progress across its rare disease programs and anticipates several data milestones in the coming months. The company's ability to beat analyst expectations on its loss per share, coupled with positive clinical updates, provides a favorable outlook for its ongoing development efforts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.